WallStreetZenWallStreetZen

NASDAQ: IMPL
Impel Pharmaceuticals Inc Stock Ownership - Who owns Impel Pharmaceuticals?

Insider buying vs selling

Have Impel Pharmaceuticals Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
John Harold LeamanChief Fin. Business Officer2022-12-313,627$3.75
$13.60kSell

1 of 1

IMPL insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when IMPL insiders and whales buy or sell their stock.

IMPL Shareholders

What type of owners hold Impel Pharmaceuticals Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Kohlberg Kravis Roberts Co LP17.31%4,135,971$1.73MInstitution
Kkr Iris Investors LLC15.91%3,802,638$1.59MInsider
Nvp Associates LLC12.88%3,077,198$1.29MInstitution
Norwest Venture Partners Xiv LP12.88%3,077,198$1.29MInsider
5am Venture Management LLC12.07%2,884,791$1.21MInstitution
Vivo Capital LLC12.07%2,884,789$1.21MInstitution
Venbio Partners LLC11.55%2,759,791$1.15MInstitution
Venbio Global Strategic Fund Ii LP11.55%2,759,791$1.15MInsider
5am Ventures V LP2.41%575,000$240.35kInsider
Vanguard Group Inc2.11%505,231$211.19kInstitution

1 of 3

IMPL vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
IMPL61.18%38.82%Net Selling
FRES0.00%0.00%
TOVX6.23%1.47%Net Buying
GOVX0.60%99.40%Net BuyingNet Buying
BCEL31.33%21.52%Net SellingNet Selling

Impel Pharmaceuticals Stock Ownership FAQ

Who owns Impel Pharmaceuticals?

Impel Pharmaceuticals (NASDAQ: IMPL) is owned by 71.53% institutional shareholders, 45.39% Impel Pharmaceuticals insiders, and 0.00% retail investors. Kkr Iris Investors LLC is the largest individual Impel Pharmaceuticals shareholder, owning 3.80M shares representing 15.91% of the company. Kkr Iris Investors LLC's Impel Pharmaceuticals shares are currently valued at $1.64M.

If you're new to stock investing, here's how to buy Impel Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.